表紙SALE
市場調查報告書

脫髮症治療藥的全球市場:2016∼2020年

Global Alopecia Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 397951
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
脫髮症治療藥的全球市場:2016∼2020年 Global Alopecia Drugs Market 2016-2020
出版日期: 2016年11月15日內容資訊: 英文 76 Pages
簡介

脫髮症發病不論年齡、性別,原因不明,不過可能來自不規則的生活和不健康的減肥、藥物治療的副作用等。全球脫髮症治療藥市場,預計2016∼2020年以5.02%的年複合成長率擴大。

本報告提供全球脫髮症治療藥市場相關調查,市場趨勢與課題,各地區趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 脫髮症:概要

  • 脫毛的原因
  • 症狀和治療

第6章 產品研發線

第7章 市場情況

  • 市場規模與預測
  • 波特的五力分析

第7章 各手術用途市場市場區隔

  • 前列腺切除
  • 腎摘出
  • 其他

第8章 主要購買標準

第9章 各給藥途徑市場區隔

  • 局部的藥物
  • 口服藥物
  • 注射劑

第10章 性別市場區隔

第11章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第12章 推動市場的要素

  • 生活方式的變化
  • 仿單標示外及OTC藥物受歡迎
  • 已通過核准治療方法的引進高

第13章 促進要素的影響

第14章 市場課題

第15章 促進要素與課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 其他值得注意的供應商

第18章 主要供應商分析

  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

第19章 附錄

第20章 關於Technavio

目錄
Product Code: IRTNTR10797

About Alopecia Drugs

Alopecia is a loss of hair and can occur at any age across the genders. The exact cause of this disorder is unknown, but many factors are assumed to be responsible for developing alopecia. Few of the primary ones are a sedentary lifestyle, unhealthy diets, and side effects of certain medical treatments. Moreover, hormonal imbalance and aging increase the probability of developing a chronic disease like cancer, arthritis, depression, and hypertension, which would also lead to hair loss, especially among middle-to-late-aged people.

Technavio's analysts forecast the global alopecia drugs market to grow at a CAGR of 5.02% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global alopecia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of alopecia drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Alopecia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Other Prominent Vendors

  • Aclaris Therapeutics
  • Actelion Pharmaceuticals
  • Almirall
  • AndroScience
  • Anterios
  • Aqua Pharmaceuticals
  • Astellas Pharma
  • Bayer HealthCare
  • BERG Health
  • BiologicsMD
  • BioPharmX
  • Celtaxsys
  • Cipher Pharmaceuticals
  • Concert Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Dermira
  • Elorac
  • F. Hoffmann-La Roche
  • Foamix
  • Guthy-Renker
  • Helix BioMedix
  • Hygeia Therapeutics
  • Hyundai Pharm
  • Incyte
  • Kasiak Research
  • Kythera Biopharmaceuticals
  • Mylan
  • NovaLead Pharma
  • Novan
  • Oculus Innovative Sciences
  • Paratek Pharmaceuticals
  • Photocure
  • Polichem
  • Promius Pharma
  • Ranbaxy Laboratories
  • Reckitt Benckiser
  • Regience
  • Samumed
  • RepliCel
  • Skinvisible Pharmaceuticals
  • Teva Pharmaceutical
  • Versapharm
  • XBiotech

Market driver

  • Popularity of off-label and OTC drugs
  • For a full, detailed list, view our report

Market challenge

  • Limited availability of approved drugs
  • For a full, detailed list, view our report

Market trend

  • Emergence of laser technology and platelet-rich plasma (PRP) therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview: Alopecia

  • Causes of hair loss
  • Hair loss: Symptoms and treatment

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Key buying criteria

PART 09: Market segmentation by ROA

  • Global topical alopecia drugs market
  • Global oral alopecia drugs market
  • Global injectable alopecia drugs market

PART 10: Market segmentation by gender

PART 11: Geographical segmentation

  • Alopecia drugs market in Americas
  • Alopecia drugs market in EMEA
  • Alopecia drugs market in APAC

PART 12: Market drivers

  • Lifestyle changes
  • Popularity of off-label and OTC drugs
  • High uptake of approved therapies

PART 13: Impact of drivers

PART 14: Market challenges

  • Poor patient adherence
  • Preference for alternative therapies
  • Limited approved therapies

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Focus on regenerative medicines
  • Emergence of laser technology and PRP therapy
  • Launch of new products

PART 17: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 18: Key vendor analysis

  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Major types of alopecia
  • Exhibit 03: Major factors responsible for hair loss
  • Exhibit 04: Symptoms and treatment of hair loss
  • Exhibit 05: Pipeline analysis of major companies for global alopecia drugs market
  • Exhibit 06: Share of pipeline molecules in global alopecia drugs market
  • Exhibit 07: Pipeline analysis of major companies for global alopecia drugs market
  • Exhibit 08: Market snapshot: Global alopecia drugs market
  • Exhibit 09: Incidence rates of alopecia areata 2015 (in percentage of population)
  • Exhibit 10: Possibility of hair loss (men) grows with age 2015
  • Exhibit 11: Distribution of population aged 60 years and over (millions)
  • Exhibit 12: Factors influencing the global alopecia drugs market 2015
  • Exhibit 13: Global alopecia drugs market snapshot: Developed and emerging markets 2015
  • Exhibit 14: Global alopecia drugs market 2015-2020 ($ billions)
  • Exhibit 15: Hair loss treatment cost
  • Exhibit 16: Key strategies in global alopecia drugs market
  • Exhibit 17: Five forces analysis
  • Exhibit 18: Key buying criteria for alopecia drugs market
  • Exhibit 19: Key buying criteria for global alopecia drugs market 2015
  • Exhibit 20: Impact of key customer segments on global alopecia drugs market 2015
  • Exhibit 21: Global alopecia drugs segmentation market by route of administration
  • Exhibit 22: Global alopecia drugs market: Segmentation by type 2015-2020
  • Exhibit 23: Global alopecia drugs market segmentation: Growth cycle analysis
  • Exhibit 24: Global topical alopecia drugs market 2015-2020 ($ billions)
  • Exhibit 25: Global oral alopecia drugs market 2015-2020 ($ millions)
  • Exhibit 26: Global injectable alopecia drugs market 2015-2020 ($ millions)
  • Exhibit 27: Snapshot of global alopecia drugs market by gender
  • Exhibit 28: Willingness toward treatment among individuals affected with hair loss
  • Exhibit 29: Snapshot of global alopecia drugs market by geography
  • Exhibit 30: Global alopecia drugs market: Country analysis based on revenue and growth rate
  • Exhibit 31: Global alopecia drugs market segmentation by geography 2015-2020 ($ millions)
  • Exhibit 32: Overview of alopecia drugs market in Americas
  • Exhibit 33: Prevalence of alopecia areata in Americas 2015 (millions)
  • Exhibit 34: Alopecia drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 35: Overview of alopecia drugs market in EMEA
  • Exhibit 36: Alopecia drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 37: Prevalence of alopecia areata in EMEA 2015 (millions)
  • Exhibit 38: Overview of alopecia drugs market in APAC
  • Exhibit 39: Alopecia drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 40: Prevalence of alopecia areata in APAC 2015 (millions)
  • Exhibit 41: Impact of alcohol on hair loss
  • Exhibit 42: Impact of stress on hair loss
  • Exhibit 43: Off-label usage: Tagamet (cimetidine) for the treatment of alopecia
  • Exhibit 44: Few of the popular OTC drugs used for the treatment of alopecia
  • Exhibit 45: Market scenario of leading Alopecia drugs: Present and future
  • Exhibit 46: Impact of drivers
  • Exhibit 47: Side effects associated with approved therapies
  • Exhibit 48: Hair loss surgeries performed in 2015
  • Exhibit 49: Number of hair restoration procedures worldwide 2015
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Overview of alopecia in regenerative medicine market
  • Exhibit 52: Variety of growth factors released from PRP therapy
  • Exhibit 53: List of pipeline candidates for alopecia treatment
  • Exhibit 54: Competitive structure analysis of global alopecia drugs market 2015
  • Exhibit 55: Performance/initiatives of existing and upcoming vendors in global alopecia drugs market
  • Exhibit 56: Geographical presence of key vendors
  • Exhibit 57: GlaxoSmithKline: Profile
  • Exhibit 58: GlaxoSmithKline: Strength assessment
  • Exhibit 59: GlaxoSmithKline: Strategy assessment
  • Exhibit 60: GlaxoSmithKline: Opportunity assessment
  • Exhibit 61: Johnson & Johnson: Strength assessment
  • Exhibit 62: Johnson & Johnson: Strategy assessment
  • Exhibit 63: Johnson & Johnson: Opportunity assessment
  • Exhibit 64: Merck: Strength assessment
  • Exhibit 65: Merck: Strategy assessment
  • Exhibit 66: Merck: Opportunity assessment
Back to Top